INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) updates on four early clinical trials with IPH2101 in Multiple Myeloma

Transparency directive : regulatory news

11/12/2012 07:15

PRESS RELEASE

                            UPDATE ON CLINICAL TRIALS
                         WITH IPH2101 IN MULTIPLE MYELOMA

Marseilles, France, December 11, 2012
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the
innate immunity company developing first-in-class drugs for cancer and
inflammatory diseases, updates on four early clinical trials with IPH2101
(hybridoma anti-KIR antibody) in Multiple Myeloma ("MM").

- Interim data of Phase I trial KIRIMID presented at ASH: a poster describing
interim data from the Phase I study KIRIMID, investigating the safety and
tolerability of the combination of IPH2101 with lenalidomide in patients with
relapsed MM following one or two lines of prior therapy was presented at the
2012 American Society of Hematology ("ASH") meeting by Don Benson, MD, PhD
(Division of Hematology/ Oncology, Ohio State Cancer Center, Columbus, OH).
The poster is available on Innate Pharma's
website: http://www.innatepharma.com/sites/default/files/ash_2012_
antikir_and_lena_phase_1_poster.pdf.

- Publication of Phase I results of IPH2101 in MM in Blood: the results of the
Phase I trial of IPH2101 in 32 patients with relapsed/refractory MM were
published online in the journal Blood. Patients were treated with IPH2101 for
up to 4 cycles without achieving dose-limiting toxicity (DLT) or reaching
maximal tolerated dose (MTD). Analysis of PK data demonstrated a clear
relationship between dose and drug concentration.

Innate Pharma also reports the results of the Phase IIa trials REMYKIR and
KIRMONO. IPH2101, tested as a single agent in patients with stable measurable
MM after induction therapy (REMYKIR study) and in patients with previously
untreated smoldering myeloma (KIRMONO study), did not show significant
reductions in M-protein levels, the primary efficacy endpoint of the studies.
The safety profile of IPH2101 was satisfactory.

Marcel Rozencweig, Executive Vice President and Chief Medical Officer of
Innate Pharma, said: "These published data were obtained with our first
generation anti-KIR antibody. IPH2102/BMS-986015 is a second generation
anti-KIR antibody that has been selected for further development and patients
are now being treated with IPH2102 in the recently announced Phase II
single-agent trial in Acute Myeloid Leukemia and the Phase I combination trial
with the Anti-PD-1 antibody nivolumab in solid tumors."

About IPH2101:
IPH2101 is an anti-KIR monoclonal antibody, produced in hybridoma cell lines,
which has been developed and tested in an early development plan for the IPH21
program.

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with
two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 81 employees as at
September 30, 2012.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code           FR0010331421
Ticker code         IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http ://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                   ATCG Press
Laure-Hélène Mercier            Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87     Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com     mb@atcg-partners.com

121211 Update on trials with IPH2101

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) updates on four early clinical trials with IPH2101 in Multiple Myeloma

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories